12.14.21 -- Taking Biotherapeutic Candidates From Late Discovery To The Clinic

Many initially promising biotherapeutic candidates fail due to lack of efficacy or safety, but there are candidates that fail due to stability, aggregation, and other issues related to cell line or process issues. 

Despite the potential of ADCs and other bioconjugates, they present a wide range of challenges for drug manufacturers trying to navigate their way to commercial success.

Find recommendations for immobilization of histidine-tagged molecules (ligands) by capture to an anti-histidine antibody covalently coupled to a sensor chip surface.

Over the last 5 years, the use of 24-well cell culture plates in laboratory applications has substantially increased. This market segment has expanded at an estimated 14% compound annual growth rate (CAGR) — a pace that is expected to continue in coming years. 

A biopharma company that supports drug discovery activities had been using a legacy plug-in to Microsoft Excel spreadsheet software for performing scientific data aggregation, analysis and presentation. By implementing a faster, more purpose-built tool running BIOVIA Pipeline Pilot protocols in Microsoft Excel spreadsheets the company has much more than simple spreadsheet capabilities.

Scientists are harnessing the power of cellular machinery to produce therapeutic biologics that can target specific conditions. Learn about the process of developing a biologic treatment, from cell line development all the way to the patient.